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Livers from hypophysectomizod rata had low levels of glyccraldehyde 3-phosphate dehydrogenase mRNA. Administration of L-triiodothyronine 
increased these levels over 20-fold. The peak response was seen 72 h after hormone administration. A half-maximal response was obtained with 
5 cg of TJ per 100 g of body weight. Thus the expression of hepatic glyceraldehyde 3.phosphate dehydrogenase appears to be regulated by thyroid 
hormone. 
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1. INTRODUCTION 
Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) is a glycolytic enzyme which exists as a 
tetramer of identical subunits each with a molecular 
weight of 37 000. The structure of GAPDH is known at 
3 A resolution [I]. The enzyme has a dinucleotide fold. 
Full length cDNAs for GAPDH have been isolated [2]. 
Since the reaction catalyzed by GAPDH is not con- 
sidered a major site of regulation of the glycolytic 
pathway, relatively few studies of the regulation of ex- 
pression of this gene have been reported. However, it 
has been demonstrated that insulin acts to increase 
GAPDH mRNA levels in adipocytes and hepatoma 
cells [3,4]. This increase in mRNA occurs very rapidly 
(within 1 to 2 h) and is due to increased transcription of 
the GAPDH gene mediated via c&acting sequences in
the 5’ flanking region [4]. In thyroid cells TSH acts to 
increase GAPDH mRNA levels by stabilizing the 
mRNA [S]. 
The cDPlA for GAPDH has been, perhaps, most ex- 
tensively used as an internal control in Northern blot- 
ting and run-on transcription analysis, see for example 
[6-l I], In this regard, GAPDH was likely selected 
because it is believed to be constitutively expressed at 
high levels in all tissues. In our studies [12] on the hor- 
monal regulation of key proteins involved in cholesterol 
homeostasis, we selected GAPDH as an internal stan- 
dard particularly for tissue comparison studies. Much 
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to our surprise GAPDH mRNA levels were markedly 
increased in liver by thyroid hormone administration. 
2. MATERIALS AND METHODS 
Male hppophysectomized Sprague-Dawley rats weighing 125-150 g
were purchased from Harlan Industries of Madison, WI. The rats 
were injected with TJ in doses ranging from 5 to 100 fig per 100 g of 
body weight and killed at the indicated times after administration of 
Tj. Some hypophysectomized rats were placed on diets containing 
0.5% desiccated thyroid powder for 8 days. All animals were killed aI 
the midpoint of the dark cycle [ 12). Poly A+ RNA was prepared from 
I g portions of their livers [12]. The cDNA probes for human catalase 
and GAPDH, pCATl0 and pHc GAP respectively, were obtained 
from American Type Culture Collection. These probes were labeled 
with “P by nick translation and bybriditcd as previously described 
[12]. The resulting autoradiograms were scanned with a laser den- 
sitometer to determine relative mRNA levels. The values for GAPDH 
were corrected using catalase as the internal control. 
3. RESULTS 
As shown in Fig. 1, hepatic GAPDH mRNA levels 
were quite low in hypophysectomized rats. Administra- 
tion of TJ resulted in over a 20-fold increase in GAPDH 
mRNA levels. This increase occurred slowly with the 
maximal response reached 72 h after TJ administration. 
When hypophysectomized rats were rendered thyrotox- 
ic by feeding desiccated thyroid powder (TP lanes of 
Fig. 1). no further increase in GADPH mRNA levels 
was seen. In terms of dose, it was found that 5 pg per 
100 g of body weight was sufficient to obtain half- 
maximal response (Fig. 1). 
4. DISCUSSION 
The data presented here suggest hat the expression 
of glyceraldehyde 3-phosphate dehydrogenase is 
regulated by thyroid hormone in addition to the 
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Fig. 1. The effect of thyroid hormone treatment of hypophysectomized rats on hepatic GAPDH mRNA. levels. Hypophysectomized rats were in- 
jected with 100 sg per 100 g of body weight of TX and killed 6-96 h later, or with S-50 pg per 100 g of body weight and killed !2 h later. Some 
hypophysectomized rats were fed 0.5% desiccated thyroid powder for 8 days (TP). Ten pg of poly A + RNA were applied to each lane and separated 
on a 1% agarosc gel [It] as described. The migration positions for catalase (CAT) and GAPDH mRNAs are labeled. The relative levels for GAPDH 
mRNA determined by laser dcnsitometry were: hypophysectomized control (0 h), 0.66; 6 h, 1 .OQ; 12 h, I .63; I8 h, 3.38; 24 h, 3.29; 48 h. 7.00; 
72 h. 14.88; 96 h, 10.12; TP, 14.39; TP, 11.98; 5 fig, 6.07; IOgg, 6.11; 25 pg, 4.05 and 50 ~g. 10.83. 
previously reported [3,4] regulation by insulin. In con- 
trast with the rapid (within 1 h) increase seen in 
response to insulin, the thyroid hormone response re- 
quired 72 h. This would be consistent with TJ acting 
post-transcriptionally to stabilize GAPDH mRNA 
rather than at the transcriptional level as in the case of 
insulin [3,4]. Stabilization of several other mRNAs by 
thyroid hormone has been reported [13-151. It was also 
reported that GADPH mRNA was stabilized by the ac- 
tion of TSH in thyroid cells [S]. 
GAPDH catalyzes a branchpoint reaction in 
glycolysis and therefore can be considered a logical site 
for regulation. Glyceraldehyde 3-phosphate can enter 
the hexose monophosphate shunt through the actions 
of transaldolase or transketolase or it can be converted 
to dihydroxyacetone phosphate by the action of triose 
phosphate isomerase and supply the glycerol backbone 
for triglyceride and phospholipid synthesis in addition 
to being converted to 1,3-djphosphoglycerate by 
GAPDH which is the first step in the production of lac- 
tate from trioses. GAPDH activity has been shown to 
be regulated by several glycolytic intermediates [16]. 
l[t appears that the increase in hepatic GAPDH 
mRNA levels caused by T3 may be a physiological 
response to the hormone. A half-maximal response was 
obtained with S pg TS per 100 g of body weight which 
is less than the 15.6 ~18 per 100 g of body weight required 
to achieve 95% saturation of nuclear T3 receptors for 4 
h [ 171. Doses of 200 pg are required to maintain 95% 
saturation for 54 h [17]. Also, we have noted that 
GAPDH mRNA levels in normal euthyroid rats were 
about 20-fold greater than those in hypophysectomized 
rats (data nor shown). Perhaps, the Ts-promoted in- 
crease in glycolysis is due, in part, to increased GAPDH 
gene expression. Also it would seem that selection of 
GAPDH as an internal control in Northern blotting 
studies [6- 111 may not be appropriate in all cases, par- 
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titularly in studies of regulation by insulin or thyroid 
hormone. 
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